Establishment Labs (ESTA) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Establishment Labs (ESTA) has outperformed NovoCure (NVCR) over the past year, gaining 57.8% versus a gain of 3.5%. Over five years, ESTA leads with a -17.1% price change compared with -86.9% for NVCR. Establishment Labs is the larger company by market cap ($1.90 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESTA | NVCR |
|---|---|---|
| Share price | $63.85 | $14.66 |
| Market cap | $1.90B | $1.71B |
| 1-day change | -2.21% | -2.07% |
| YTD return | -12.39% | +13.38% |
| 1-year return | +57.85% | +3.53% |
| 5-year return | -17.08% | -86.94% |
| EPS (TTM) | $-1.30 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.59 | $21.45 |
| 52-week low | $38.38 | $9.82 |
| Distance from 52-week high | -34.57% | -31.66% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +60.44% | +83.22% |
| Average volume | 426.60K | 1.42M |
| Shares outstanding | 29.80M | 116.45M |
| Employees | 1,004 | 1,605 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESTA has outperformed NVCR by 54.3 percentage points over the past year.
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Healthcare · Medical Devices · 1,004 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Healthcare · Medical Devices · 1,605 employees
ESTA vs NVCR FAQ
Which is bigger, Establishment Labs or NovoCure?
Establishment Labs (ESTA) is larger, with a market capitalization of $1.90B compared with $1.71B for NovoCure (NVCR).
Which stock has performed better over the past year, ESTA or NVCR?
ESTA returned +57.85% over the past 12 months, compared with +3.53% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are Establishment Labs and NovoCure in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.